Pearl Fang

Pearl Fang is the Head of Clinical Development. She is responsible for building and leading Asceneuron’s clinical development strategy, including the management, operations and performance of all medical activities. Pearl also provides clinical input into clinical trial design and execution, obtaining regulatory authority and ethics committee approvals and management of all outsourced aspects of clinical activities.

Pearl has 17 years of experience in the biopharmaceutical industry. This includes roles in clinical development, clinical operations and medical affairs in neurodegeneration, oncology, hematology and autoimmune disorders. Most recently, Pearl was the Vice President of Clinical Development and Clinical Operations at NKMax America, Inc. Previously, she worked at ARMO Biosciences, Puma Biotechnology, Amgen, Inc., Onyx, Inc., Cephalon, and Eli Lilly and Company.

Pearl graduated from the University of Southern California (USC) with her B.A., M.A. and Ph.D. in Clinical Neuroscience.